| scholarly article | Q13442814 |
| P50 | author | Adrian S. Ray | Q40567817 |
| P2093 | author name string | Michael J M Hitchcock | |
| Marshall W Fordyce | |||
| P2860 | cites work | Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review | Q22242702 |
| Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors | Q24536268 | ||
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity | Q39008333 | ||
| Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. | Q39118603 | ||
| The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients | Q40039677 | ||
| Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. | Q40100382 | ||
| Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy | Q40676324 | ||
| Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials | Q41044551 | ||
| Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study | Q41339429 | ||
| Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection | Q41633359 | ||
| Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. | Q41984465 | ||
| Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study | Q42213339 | ||
| Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors | Q42231771 | ||
| Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults | Q42287616 | ||
| Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs | Q43741891 | ||
| Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs | Q44534469 | ||
| Combination antiretroviral therapy and the risk of myocardial infarction | Q44662157 | ||
| Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial | Q44975155 | ||
| Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. | Q45836204 | ||
| Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens | Q46595288 | ||
| Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents | Q48738533 | ||
| The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years | Q50156872 | ||
| Projected life expectancy of people with HIV according to timing of diagnosis | Q57476832 | ||
| Distribution of lysosomal protective protein in human tissues | Q72903562 | ||
| Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro | Q24633870 | ||
| Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine | Q28378681 | ||
| Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA | Q28379404 | ||
| Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012 | Q28533843 | ||
| Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study | Q31146395 | ||
| Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults | Q33460754 | ||
| Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients | Q33645750 | ||
| Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. | Q33697044 | ||
| Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue | Q33769993 | ||
| Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients | Q33770032 | ||
| Effect of early versus deferred antiretroviral therapy for HIV on survival | Q33789114 | ||
| A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. | Q34032537 | ||
| Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. | Q34068078 | ||
| Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. | Q34088490 | ||
| Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood | Q34091731 | ||
| Changes in the risk of death after HIV seroconversion compared with mortality in the general population | Q34791057 | ||
| Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis | Q35746114 | ||
| In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate. | Q36075908 | ||
| Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro | Q36076011 | ||
| Markers of renal disease and function are associated with systemic inflammation in HIV infection | Q36206108 | ||
| Perspectives on the development of acyclic nucleotide analogs as antiviral drugs | Q36534380 | ||
| Association of tenofovir exposure with kidney disease risk in HIV infection | Q37077982 | ||
| Renal function with use of a tenofovir-containing initial antiretroviral regimen | Q37215065 | ||
| Continuous antiretroviral therapy decreases bone mineral density | Q37357149 | ||
| Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys | Q37421891 | ||
| Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. | Q37439827 | ||
| Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202 | Q37619346 | ||
| Osteoporosis and bone health in HIV. | Q38009732 | ||
| The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care | Q38023235 | ||
| Mechanism of active renal tubular efflux of tenofovir | Q38665179 | ||
| Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial | Q38905814 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virology | Q7215 |
| tenofovir | Q155954 | ||
| tenofovir alafenamide fumarate | Q27162911 | ||
| P304 | page(s) | 63-70 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Antiviral Research | Q4775352 |
| P1476 | title | Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus | |
| P478 | volume | 125 |
| Q91966181 | A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide |
| Q92216742 | A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques |
| Q53702307 | A competitive lateral flow assay for the detection of tenofovir. |
| Q90125534 | A long acting nanoformulated lamivudine ProTide |
| Q90685506 | A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice |
| Q90416293 | Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review |
| Q92040505 | Antiviral agents against African swine fever virus |
| Q92705220 | Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials |
| Q27755387 | Approved Antiviral Drugs over the Past 50 Years |
| Q40514370 | Bifunctional aryloxyphosphoramidate prodrugs of 2'-C-Me-uridine: synthesis and anti-HCV activity |
| Q38835028 | Bone Loss in HIV Infection |
| Q64118054 | Canadian guideline on HIV preexposure prophylaxis and nonoccupational postexposure prophylaxis for pharmacists |
| Q40597405 | Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection |
| Q38821304 | Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments |
| Q38846571 | Complications of Treatment in Youth with HIV. |
| Q114704049 | Current Trends and Limitations in Dengue Antiviral Research |
| Q59358518 | Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection |
| Q59126145 | Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era |
| Q91977337 | Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate |
| Q61820482 | Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid |
| Q58092929 | Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract |
| Q38974893 | Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products. |
| Q52664377 | Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection. |
| Q39426047 | Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients |
| Q61796692 | Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells |
| Q56763232 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs |
| Q64947150 | Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient. |
| Q52691809 | Flexibility-Not just for yoga anymore! |
| Q30249771 | HIV infection and bone disease |
| Q56992437 | Harnessing nanostructured systems for improved treatment and prevention of HIV disease |
| Q48191650 | Hepatitis in AIDS patients |
| Q50171127 | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates |
| Q47151161 | Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells |
| Q54246489 | How to Control HTLV-1-Associated Diseases: Preventing de Novo Cellular Infection Using Antiviral Therapy. |
| Q55303657 | Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected Nigerian patients. |
| Q92730901 | Kidney Disease in HIV Infection |
| Q90655875 | Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia |
| Q64890616 | Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults. |
| Q39371494 | Long acting systemic HIV pre-exposure prophylaxis: an examination of the field |
| Q42334096 | Long-Acting HIV Treatment and Prevention: Closer to the Threshold |
| Q36262152 | Long-acting slow effective release antiretroviral therapy |
| Q90701961 | Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission |
| Q41923505 | Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model |
| Q54256710 | Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. |
| Q46130631 | Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells |
| Q47574017 | Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics |
| Q98292337 | Pharmaceutical Approaches to HIV Treatment and Prevention |
| Q37669191 | Pharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigations |
| Q90459684 | Pharmacology of Symtuza® (DRV/c/FTC/TAF) |
| Q88786491 | Phosphoramidates and phosphonamidates (ProTides) with antiviral activity |
| Q90012058 | Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen |
| Q40401616 | Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen |
| Q90915645 | Preparation of Pyrimidine Alkenyl Acyclic Nucleoside Phosphonoamidates |
| Q40561708 | Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection |
| Q101210395 | RTC binds NRTIs |
| Q95541844 | Reply |
| Q90255400 | Repurposing Antiviral Drugs for Orthogonal RNA-Catalyzed Labeling of RNA |
| Q38802093 | Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients |
| Q50080891 | Role of tenofovir alafenamide in the jungle of antiretroviral prescription |
| Q90568453 | Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial |
| Q39022885 | Single-Tablet Regimens for the Treatment of HIV-1 Infection |
| Q90329919 | Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid |
| Q91356183 | Symmetrical Diamidates as a Class of Phosphate Prodrugs to Deliver the 5'-Monophosphate Forms of Anticancer Nucleoside Analogues |
| Q47601762 | Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs |
| Q42196760 | Synthetic Approaches for the Preparation of Phosphoramidate Prodrugs of 2'-Deoxypseudoisocytidine. |
| Q38910661 | Tenofovir Alafenamide |
| Q95363291 | Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity |
| Q39298139 | Tenofovir Alafenamide: A Review in Chronic Hepatitis B. |
| Q47142298 | Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy |
| Q54230654 | Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? |
| Q40731833 | Tenofovir alafenamide: safer, but questions remain |
| Q40089234 | The ProTide Prodrug Technology: From the Concept to the Clinic |
| Q52323442 | The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. |
| Q52560078 | The expanding role of prodrugs in contemporary drug design and development. |
| Q99712747 | The first case of HIV-2 in Scotland |
| Q91710394 | Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide |
| Q50059498 | Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs |
| Q36275141 | Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations |
| Q39065035 | Viral reverse transcriptases. |
| Q33765196 | When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank |
Search more.